3 ms·
As an IPO this sounds similar to most biotech/pharma startups. These companies routinely IPO in the $50-100 million range when all they have is a patent, some p
by pavlov 11y ago
As an IPO this sounds similar to most biotech/pharma startups. These companies routinely IPO in the $50-100 million range when all they have is a patent, some promising data but no approved clinical trials and no business.
Of course it's different because there's a clear post-IPO acquisition market for biotechs. Not quite as clear who would buy Hyperloop if it's proven to work...
- bliti 11y agoIt seems to be related to how startups are suddenly valuated at billions without much of a moat or intrinsic value. Just for having "users".
- minot 11y agoMeh. If I give you $100 for a 1*10^-6% stake in your company with a guarantee that you will pay me back at least $100 before honoring any other debts or issue, are you really a ten billion dollar startup?
- zaroth 11y agoIt's most entertaining to subtract any preference off the top of the valuation. I wish it became a trend. Particularly for preferences with multipliers!